Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection

about

Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection

Item

http://www.wikidata.org/entity/Q42031296

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection

@en

Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection

@nl

type

Item

label

Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection

@en

Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection

@nl

prefLabel

Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection

@en

Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection

@nl

P1476

Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection

@en

P2093

Bosco A Paes

http://www.w3.org/2001/XMLSchema#string

P2860

Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia.

A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection

The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation.

Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.

Prevention of respiratory syncytial virus infection

The cost effectiveness of palivizumab: a systematic review of the evidence.

Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: What are we trying to prevent?

Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.

Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants.

Palivizumab for the prevention of respiratory syncytial virus infection.

P304

988-991

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Krista L Lanctôt

Kelly Smart

P577

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20944037

http://www.w3.org/2001/XMLSchema#string

P932

2954075

http://www.w3.org/2001/XMLSchema#string